Literature DB >> 33798666

Nano-delivery systems focused on tumor microenvironment regulation and biomimetic strategies for treatment of breast cancer metastasis.

Xiaoyan Gu1, Yunzhen Gao1, Ping Wang1, Lixin Wang2, Haibao Peng1, Yuanzhi He1, Ying Liu3, Nianping Feng4.   

Abstract

Breast cancer metastasis and recurrence accounts for vast majority of breast cancer-induced mortality. Tumor microenvironment (TME) plays an important role at each step of metastasis, evasion of immunosurveillance, and therapeutic resistance. Consequently, TME-targeting alternatives to traditional therapies focused on breast cancer cells are gaining increasing attention. These new therapies involve the use of tumor cells, and key TME components or secreted bioactive molecules as therapeutic targets, alone or in combination. Recently, TME-related nanoparticles have been developed to deliver various agents, such as bioactive ingredients extracted from natural sources or chemotherapeutic agents, genes, proteins, small interfering RNAs, and vaccines; they have shown great therapeutic potential against breast cancer metastasis. Among various types of nanoparticles, biomimetic nanovesicles are a promising means of addressing the limitations of conventional nanocarriers. This review highlights various nanoparticles related to or mediated by TME according to the key TME components responsible for metastasis. Furthermore, TME-related biomimetic nanoparticles against breast cancer metastasis have garnered attention owing to their promising efficiency, especially in payload delivery and therapeutic action. Here, we summarize recent representative studies on nanoparticles related to cancer-associated fibroblasts, extracellular matrix, endothelial cells, angiogenesis, and immune cells, as well as advanced biomimetic nanoparticles. Future challenges and opportunities in the field are also discussed.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomimetic nanoparticle; Breast cancer metastasis; Combinatorial therapy; Nano-delivery system; Tumor microenvironment

Year:  2021        PMID: 33798666     DOI: 10.1016/j.jconrel.2021.03.039

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  6 in total

Review 1.  Nanobiotherapeutic strategies to target immune microenvironment of triple-negative breast cancer.

Authors:  Qing Chang; Liang Chang; Mo Li; Liwen Fan; Shunchao Bao; Xinyu Wang; Linlin Liu
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

Review 2.  Smart Nanoparticles for Breast Cancer Treatment Based on the Tumor Microenvironment.

Authors:  Xiao Luo; Qi Zhang; Hongbo Chen; Kai Hou; Ning Zeng; Yiping Wu
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

3.  Improving cellular uptake and bioavailability of periplocymarin-linoleic acid prodrug by combining PEGylated liposome.

Authors:  Huiyun Zhang; Shunru Wei; Yu Zhang; Anran Pan; Michael Adu-Frimpong; Congyong Sun; Gang Qi
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

Review 4.  Tumor extracellular matrix modulating strategies for enhanced antitumor therapy of nanomedicines.

Authors:  Meng Li; Yijing Zhang; Qin Zhang; Jingchao Li
Journal:  Mater Today Bio       Date:  2022-07-15

Review 5.  Cell membrane coated-nanoparticles for cancer immunotherapy.

Authors:  Yingping Zeng; Sufen Li; Shufen Zhang; Li Wang; Hong Yuan; Fuqiang Hu
Journal:  Acta Pharm Sin B       Date:  2022-02-28       Impact factor: 14.903

6.  Cannabidiol loaded extracellular vesicles sensitize triple-negative breast cancer to doxorubicin in both in-vitro and in vivo models.

Authors:  Nilkumar Patel; Nagavendra Kommineni; Sunil Kumar Surapaneni; Anil Kalvala; Xuegang Yaun; Aragaw Gebeyehu; Peggy Arthur; Leanne C Duke; Sara B York; Arvind Bagde; David G Meckes; Mandip Singh
Journal:  Int J Pharm       Date:  2021-07-27       Impact factor: 6.510

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.